Completed PHASE3 INTERVENTIONAL NCT00312806

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks

Sponsor: Takeda

Conditions Gastroesophageal Reflux Disease (GERD)

Interventions Pantoprazole

Updated 7 times since 2017 Last updated: May 4, 2012 Started: May 31, 2006 Primary completion: Mar 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00312806, this PHASE3 trial focuses on Gastroesophageal Reflux Disease (GERD) and remains completed. Sponsored by Takeda, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Dec 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, BC, Canada , Agen, France , Amadora, Portugal , Aviano (Pordenone), Italy , Barcelona, Spain , Bari, Italy , Basel, Switzerland , Bath, United Kingdom , Bedford Park SA, Australia , Belo Horizonte - Minas Gerais, Brazil and 147 more locations